Skip to main content
. Author manuscript; available in PMC: 2016 Nov 1.
Published in final edited form as: Antiviral Res. 2015 Sep 25;123:114–119. doi: 10.1016/j.antiviral.2015.09.008

Figure 2.

Figure 2

IgG and IgA levels in serum of subjects before, 30 days after and 90 days after receiving DAS181 by inhalation for 1, 3 or 10 days.

IgG and IgA levels are arbitrary units based on a standard curve of dilutions of a serum with high titers. The lower limit for each assay is shown by the horizontal hatched line: 0.2 for IgG titers and 0.1 for IgA titers.

Subject number followed by “P” = placebo recipient

Three subjects in the 10-day cohort stopped dosing early: Subject 2007 after the 4th dose for psychiatric symptoms considered to be treatment-unrelated, Subject 2009 (identified by **) after the 9th dose for prolonged wheezing and coughing, and Subject 2006 (identified by *) after the 9th dose for a hypersensitivity pneumonitis syndrome.